echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > "First-in-class" anti-cancer therapy targeting Nobel Prize signaling pathway was approved by FDA

    "First-in-class" anti-cancer therapy targeting Nobel Prize signaling pathway was approved by FDA

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 13, 2021, the US FDA approved Welireg (belzutifan), a hypoxia-inducible factor inhibitor developed by Merck (MSD), for the treatment of von Hippel-Lindau (VHL) disease-related cancers, such as renal cell carcinoma (RCC), Central nervous system (CNS) hemangioblastoma or pancreatic neuroendocrine tumor (pNET), these patients do not need immediate surgical treatment


    VHL is a rare genetic disease that can abnormally activate hypoxia-inducible factor (HIF-2α) in cancer patients


    This approval is based on the results of an ongoing Phase 2 clinical trial


    ▲Belzutifan molecular structure (picture source: DMacks, Public domain, via Wikimedia Commons)

    In terms of safety, the most common adverse reactions reported in patients in the belzutifan group were decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea


    Reference materials:

    [1] FDA approves belzutifan for cancers associated with von Hippel-Lindau disease.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.